Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Other Non-Current Assets (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Other Non-Current Assets for 7 consecutive years, with $5.8 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets rose 197.44% to $5.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.8 million through Dec 2025, up 197.44% year-over-year, with the annual reading at $5.8 million for FY2025, 197.44% up from the prior year.
  • Other Non-Current Assets for Q4 2025 was $5.8 million at Kymera Therapeutics, down from $6.8 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $6.8 million in Q3 2025, with the low at $30000.0 in Q1 2021.
  • Average Other Non-Current Assets over 5 years is $4.1 million, with a median of $5.2 million recorded in 2024.
  • Peak annual rise in Other Non-Current Assets hit 20286.67% in 2021, while the deepest fall reached 84.92% in 2021.
  • Over 5 years, Other Non-Current Assets stood at $6.1 million in 2021, then plummeted by 50.67% to $3.0 million in 2022, then fell by 29.8% to $2.1 million in 2023, then fell by 7.93% to $2.0 million in 2024, then surged by 197.44% to $5.8 million in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $5.8 million, $6.8 million, and $4.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.